drugset / Trial / NCT07071623

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623

Phase 3 Recruiting 4580 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it

Timeline

Start
2025-11-10
Primary completion
2027-10-18
Completion
2027-10-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Emtricitabine/tenofovir disoproxil Unknown 200 mg Oral
Comparator Emtricitabine/tenofovir disoproxil Unknown 245 mg Oral
Subject MK-8527 Small molecule 11 mg Oral